Table Of Content

Subject index of volume 110 Abstinence 333 Calcium 497 Drinking behavior 5 Abstraction 219 *5Calcium uptake 133 Drug discrimination 53, 115, 209, 280, Acetylcholine 119 cAMP 37 287, 295, 309, 347 1-Acetyl-4-methylpiperazine 347 CANTAB 395 Drug interactions 302, 471 Acoustic startle reflex 379 Cat 240 Drug mixtures 309 Acquisition 5 Catecholamine receptor antagonists Dyskinesias 383 Activity 371 193 D, agonist 69 Adenosine triphosphate-sensitive potas- Catecholamines 203 D, and D, receptors 355 sium channel 500 CCK 383 D, antagonist 69 Administration 5 CCK receptors 213 D, receptor 69 Aggression 53, 451 CCK-8us-Devazepide 409 D2 receptor 152 Agonistic behavior 451 Central a-2 adrenoceptors 209 Alcoholism 181 Ceruletide 383 EDTA 497 Amnesia 181 CGS-8216 467 Elevated plus maze 490 Amnesic effect 13 L-Chiro-inositol 229 Elevated plus-maze 19, 213 Amphetamine 60, 115, 125, 152, 169, Chlordiazepoxide 60 Enhanced sensitivity 60 309, 479 Cholesterol 337 Ethanol tolerance 443 Animal behavior 451 Chronic drug use 219 Ethyl-alcohol 471 Animal model 245 Chronic treatment 140, 245 Expectancy 437 Antagonism 280 Clomipramine 302 Anticonvulsant 13 Cloned human dopamine receptors 27 Fear 245 Antidepressants 140 Clonidine 209 Feeding 193, 451 Antipanic 245 Clozapine 119, 145, 273, 365 Field conditions 371 Antipsychotic 119 Cocaine 5, 115, 169, 287, 309, 390, Flumazenil 409, 490 Anxiety 19, 198, 240, 245, 342, 368, 402, 415, 427 Fluoxetine 390 409 Cocaine sensitization 443 Fluvoxamine 302 Anxiolytic 13, 257 Coffee 45 Food 460 Anxiolytics 379 Cognition 219 Food deprivation 5 Apomorphine 97, 169, 177, 320, 427 Cognitive performance 45 Food intake 203 Apomorphine-induced stereotyped be- Conditioned avoidance response 273 havior 165 Conditioned place preference 460 GABA 443 Atropine 103 Conditioned reinforcement 355 GABA (gamma-aminobutyric acid) 295 Attention 395, 415, 479 Conditioned taste aversion 76 Gamma aminobutyric acid 368 Atypical 119 Conditioning 125 Generalization 280 Atypical antipsychotics 177 Corticosterone 467 Glucose and saccharin (G+S) 5 Autoreceptors 460 Cross-sensitization 402 Grip strength 92 Autoshaping 5 D-Cycloserine 165 Growth hormone 177 Awareness 374 C57B1/6J mice 69 GTP analogues 27 Guinea-pig 490 Baboon 1 DA autoreceptors 177 Baclofen 295 Defense 245 Haloperidol 119, 145, 187, 427 Baroreceptor stimulation 337 Delayed-matching-to-sample 327 Heart rate 37, 371 Behavior 273 Dementia of the Alzheimer type (DAT) Hedonia 460 Behavioral sensitization 320 395 Heroin 402 Behavioural sensitization 159 Dependence 19, 379 5-HT 53, 490 Benzodiazepine 181 Depression 235 5-HT>2 receptors 365 Benzodiazepine antagonist 280, 467 Desipramine 37 5-HT3 receptors 213, 257 Benzodiazepine binding sites 13 Desmethylimipramine 110 5-HT,, 390 Benzodiazepine pharmacodynamics 85 Diazepam 13, 19, 85, 280, 295, 467, 5HT,c receptor 140 Benzodiazepine receptors 198 490 Human brain 265 Benzodiazepines 240, 379, 451, 471 Diisopropylfluorophosphate 103 Human subjects 365 Beta-adrenergic receptor 110 Dimethocaine 287 Hydroxylation 302 Bezold-Jarisch reflex 257 Discrimination 1 Hyperactivity 69 Bicuculline-induced convulsion 500 Discrimination learning 76 Biphasic 69 DMPP 347 ICSS 119 Blood lipid levels 337 DN 2327 280 Imagery 219 Blood pressure 37 DOI 97 Imidazoline preferring receptors 209 Bombesin 193 Dopamine 97, 119, 145, 152, 159, Imipramine 245 Bombesin receptor antagonist 193 187, 355, 383, 402, 443, 460, 479 [SH]|mipramine binding 235 Brain 103 Dopamine agonists 27 Incentive learning 460 Brain stimulation reward 119 Dopamine antagonists 27 Informed consent 437 BRL 46470A 257 Dopamine D, receptors 27 Intravenous 5 Bromocriptine 402 Dopamine receptor subtypes 273 Intrusive thoughts 333 Buspirone 280 Dopamine receptors 265 ['?°1]-2’iodospiperone 27 Dopamine synthesis 273 lowa Tests 219 Caerulein 213 Dorsal periaqueductal grey matter 198 Isolation-induced 53 Caffeine 45, 169, 437 Double-blind design 437 Isoproterenol 37 Subject index of volume 110 Abstinence 333 Calcium 497 Drinking behavior 5 Abstraction 219 *5Calcium uptake 133 Drug discrimination 53, 115, 209, 280, Acetylcholine 119 cAMP 37 287, 295, 309, 347 1-Acetyl-4-methylpiperazine 347 CANTAB 395 Drug interactions 302, 471 Acoustic startle reflex 379 Cat 240 Drug mixtures 309 Acquisition 5 Catecholamine receptor antagonists Dyskinesias 383 Activity 371 193 D, agonist 69 Adenosine triphosphate-sensitive potas- Catecholamines 203 D, and D, receptors 355 sium channel 500 CCK 383 D, antagonist 69 Administration 5 CCK receptors 213 D, receptor 69 Aggression 53, 451 CCK-8us-Devazepide 409 D2 receptor 152 Agonistic behavior 451 Central a-2 adrenoceptors 209 Alcoholism 181 Ceruletide 383 EDTA 497 Amnesia 181 CGS-8216 467 Elevated plus maze 490 Amnesic effect 13 L-Chiro-inositol 229 Elevated plus-maze 19, 213 Amphetamine 60, 115, 125, 152, 169, Chlordiazepoxide 60 Enhanced sensitivity 60 309, 479 Cholesterol 337 Ethanol tolerance 443 Animal behavior 451 Chronic drug use 219 Ethyl-alcohol 471 Animal model 245 Chronic treatment 140, 245 Expectancy 437 Antagonism 280 Clomipramine 302 Anticonvulsant 13 Cloned human dopamine receptors 27 Fear 245 Antidepressants 140 Clonidine 209 Feeding 193, 451 Antipanic 245 Clozapine 119, 145, 273, 365 Field conditions 371 Antipsychotic 119 Cocaine 5, 115, 169, 287, 309, 390, Flumazenil 409, 490 Anxiety 19, 198, 240, 245, 342, 368, 402, 415, 427 Fluoxetine 390 409 Cocaine sensitization 443 Fluvoxamine 302 Anxiolytic 13, 257 Coffee 45 Food 460 Anxiolytics 379 Cognition 219 Food deprivation 5 Apomorphine 97, 169, 177, 320, 427 Cognitive performance 45 Food intake 203 Apomorphine-induced stereotyped be- Conditioned avoidance response 273 havior 165 Conditioned place preference 460 GABA 443 Atropine 103 Conditioned reinforcement 355 GABA (gamma-aminobutyric acid) 295 Attention 395, 415, 479 Conditioned taste aversion 76 Gamma aminobutyric acid 368 Atypical 119 Conditioning 125 Generalization 280 Atypical antipsychotics 177 Corticosterone 467 Glucose and saccharin (G+S) 5 Autoreceptors 460 Cross-sensitization 402 Grip strength 92 Autoshaping 5 D-Cycloserine 165 Growth hormone 177 Awareness 374 C57B1/6J mice 69 GTP analogues 27 Guinea-pig 490 Baboon 1 DA autoreceptors 177 Baclofen 295 Defense 245 Haloperidol 119, 145, 187, 427 Baroreceptor stimulation 337 Delayed-matching-to-sample 327 Heart rate 37, 371 Behavior 273 Dementia of the Alzheimer type (DAT) Hedonia 460 Behavioral sensitization 320 395 Heroin 402 Behavioural sensitization 159 Dependence 19, 379 5-HT 53, 490 Benzodiazepine 181 Depression 235 5-HT>2 receptors 365 Benzodiazepine antagonist 280, 467 Desipramine 37 5-HT3 receptors 213, 257 Benzodiazepine binding sites 13 Desmethylimipramine 110 5-HT,, 390 Benzodiazepine pharmacodynamics 85 Diazepam 13, 19, 85, 280, 295, 467, 5HT,c receptor 140 Benzodiazepine receptors 198 490 Human brain 265 Benzodiazepines 240, 379, 451, 471 Diisopropylfluorophosphate 103 Human subjects 365 Beta-adrenergic receptor 110 Dimethocaine 287 Hydroxylation 302 Bezold-Jarisch reflex 257 Discrimination 1 Hyperactivity 69 Bicuculline-induced convulsion 500 Discrimination learning 76 Biphasic 69 DMPP 347 ICSS 119 Blood lipid levels 337 DN 2327 280 Imagery 219 Blood pressure 37 DOI 97 Imidazoline preferring receptors 209 Bombesin 193 Dopamine 97, 119, 145, 152, 159, Imipramine 245 Bombesin receptor antagonist 193 187, 355, 383, 402, 443, 460, 479 [SH]|mipramine binding 235 Brain 103 Dopamine agonists 27 Incentive learning 460 Brain stimulation reward 119 Dopamine antagonists 27 Informed consent 437 BRL 46470A 257 Dopamine D, receptors 27 Intravenous 5 Bromocriptine 402 Dopamine receptor subtypes 273 Intrusive thoughts 333 Buspirone 280 Dopamine receptors 265 ['?°1]-2’iodospiperone 27 Dopamine synthesis 273 lowa Tests 219 Caerulein 213 Dorsal periaqueductal grey matter 198 Isolation-induced 53 Caffeine 45, 169, 437 Double-blind design 437 Isoproterenol 37 Latent inhibition 187, 479 OTC stimulants 309 Self assessment 471 Learning 219 Oxiracetam 421 Selfadministration 1, 390 Lidocaine 287 Self-stimulation 119 Ligand binding 347 Pain 337 Semantic activation 333 Lithium 229 Parabrachial nucleus 76 Sensitization 125, 402, 427 Lithium-pilocarpine seizures 229 [?H]Paroxetine binding 235 Serotonin 53, 145, 203, 390 Local anesthetics 287 Penile erection 140 Serotonin receptors 265 Locomotion 69, 97, 402 Pentobarbital 280, 295 Serotonin,¢). 97 Locomotor activity 125, 152, 320, 347, Pentylenetetrazol 280 Serotonin, receptor 110 427 Performance 415 Sertraline 203 Log-linear pharmacodynamic modeling Performance enhancement 169 Sex differences 245 PET 265 Skeletal muscle relaxants 92 Lorazepam 181, 374 Phobia 240 SKF 38393 69, 320 L-365, 260 409 Pigeons 327 SL 75102 (4{[(4-chlorophenyl) Pilocarpine 229 (5-fluoro-2-hydroxyphenyl) MAO inhibitor 140 Place preference conditioning 152, 159 methylene]amino} butyric acid) 295 Marijuana 219 Placebo 437 Smoking 337 Mecamylamine 347 Plasma concentrations 302 Smoking behavior 371 Memory 219, 395 5-Platelet HT uptake sites 235 Smooth pursuit eye movements 85 Memory and learning 421 Plus-maze 240 Social behavior 451 Mesolimbic 119 Positron emission tomography 265, Social interactions 257 Mesulergine 97 365 Sodium lactate 368 Methods 471 3-PPP 145 Somatostatin receptors 103 (+)3,4-Methylenedioxymethampheta- PRES 337 Stereoisomers 133 mine (MDMA) 327 Priming 333 Stereotypy 427 Mice 53 Procaine 287 Stimulants 92, 125, 169 Midazolarm 1 Progabide 295 Straub tail reaction 254 Mild stress 140 Prolactin 177 Stress 152, 159, 467 MK-801 125 Propranolol 110 Stroop interference 333 Moclobemide 140 (1)-Propranolol 97 Substantia nigra 119 Monoamines 273 Psychomotor performance 471 Sucrose consumption 159 Morphine 254, 500 Psychomotor stimulants 287 Sulpiride 145 Motor activity 451 Psychosis 119 (—1)-Sulpiride 165 Mouse two-compartment test 409 Synaptosomes 133 Muscimol 295 Quinpirole 152, 159, 320, 402 Muscle relaxation 92 Tail-flick 497 Myo-inositol 229 Raclopride 273 Tea 45 Myorelaxation 13 Rat 76, 103, 115, 203, 213, 280, 427, Tetrahydroaminoacridine (THA) 395 460 Thiomuscimol 295 N. accumbens 187 RRaatt ebrlaeivna ted1 10p lus-maze test 409 THIPp yri(d4i,n5-,36-,o7l-)t etr2a9h5y droisoxazolo[5,4-c] NN-aD*e-mCeat?h*y laetxicohna nge3 02 133 RRaetasc tio5n, 6t0i,m e1 59,4 151 93, 198, 287, 497 TTroilceyrcalincc e ant1i9d,e p3r2e7s sant 245 Neuroleptic 119 B-Receptor 37 Tricyclic antidepressants 133 NNeeuurroolpespytcihcosl ogi14c5a,l 3t8e3s,t s 4601 81 RReEcMo gnsilteieopn dempermivoartyi on 3741 40 TTrriichyelixcy phaentniiddeyplr ess1a1n9t s 302 Nicotine 169, 187, 333, 337, 347 Reward 152, 159, 355 Nicotine analgesia 497 Risk assessment 245 Nigrostriatal 119, 443 Risperidone 265 Ultrasounds 379 NMDA receptor antagonist 125 Nootropic drugs 421 Saccadic eye movements 85 Ventral tegmental area 119 Noradrenergic 342 Saliva 415 Vocalizations 379 Nucleus accumbens 152, 355, 479 SCH 23390 165, 320 Voltage-dependent calcium channels SCH 39166 69 133 8-OH-DPAT 97, 390 Schedule-controlled behavior 60 Ondansetron 213 Schizophrenia 119, 365, 479 Withdrawal 19, 379 Open field 213 SCH-23390 273 Opiates 76 Scopolamine 421 X-maze 257 Opioid agonists 60 Sedation 13, 374 Opioid antagonists 60, 254 Sedatives 92 YM 09151—2 165 Opioid interaction 254 Self 5 Yohimbine 342